NASDAQ:VACC Vaccitech (VACC) Stock Price, News & Analysis $1.37 -0.09 (-6.16%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$1.33▼$1.4850-Day Range$1.25▼$5.0052-Week Range$1.64▼$5.10Volume24,533 shsAverage Volume244,643 shsMarket Capitalization$52.81 millionP/E RatioN/ADividend YieldN/APrice Target$7.63 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrends Get Vaccitech alerts: Email Address Vaccitech MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside456.6% Upside$7.63 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews Sentiment0.86Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($2.41) to ($2.74) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.38 out of 5 starsMedical Sector752nd out of 936 stocksPharmaceutical Preparations Industry351st out of 436 stocks 3.3 Analyst's Opinion Consensus RatingVaccitech has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Amount of Analyst CoverageVaccitech has received no research coverage in the past 90 days.Read more about Vaccitech's stock forecast and price target. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for VACC. Previous Next 0.0 Dividend Strength Dividend YieldVaccitech does not currently pay a dividend.Dividend GrowthVaccitech does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for VACC. Previous Next 3.3 News and Social Media Coverage News SentimentVaccitech has a news sentiment score of 0.86. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Vaccitech this week, compared to 0 articles on an average week.Search Interest1 people have searched for VACC on MarketBeat in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Vaccitech insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.00% of the stock of Vaccitech is held by insiders.Percentage Held by InstitutionsOnly 26.13% of the stock of Vaccitech is held by institutions.Read more about Vaccitech's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Vaccitech are expected to decrease in the coming year, from ($2.41) to ($2.74) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Vaccitech is -0.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Vaccitech is -0.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVaccitech has a P/B Ratio of 0.21. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad American Hartford Gold GroupPrepare for a Recession Unlike Any OtherDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.GET THE FREE GUIDE About Vaccitech Stock (NASDAQ:VACC)Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. The company's therapeutic programs include VTP-300, which is in Phase 1/2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1/2a clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer. Its prophylactic programs include VTP-400, which is in preclinical stage for the prevention of herpes zoster or shingles; VTP-500 that has completed Phase 1 clinical trial for the prevention of Middle East respiratory syndrome; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious and autoimmunity diseases, and cancers. The company's therapeutic programs include VTP-300, which is in Phase 2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1b/2 clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer. Its prophylactic programs include VTP-400, which is in preclinical stage for the prevention of herpes zoster or shingles; VTP-500 that has completed Phase 1 clinical trial for the prevention of Middle East respiratory syndrome; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech Rx Limited and changed its name to Vaccitech plc in March 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, the United Kingdom.Vaccitech Rx Limited and changed its name to Vaccitech plc in March 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, the United Kingdom.Read More VACC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VACC Stock News HeadlinesJuly 22, 2024 | americanbankingnews.comComparing CytoDyn (OTCMKTS:CYDY) & Vaccitech (NASDAQ:VACC)May 22, 2024 | markets.businessinsider.comBarinthus Bio to Present VTP-300 Clinical Data Updates at EASL Congress 2024July 26, 2024 | WealthPress (Ad)This TSLA short trade is on a nine win hot streakMost Tesla Shareholders are disappointed in the stock's performance in 2024. Year to date, it's down 30%... And things don’t seem to be getting better. That said, one professional trader has found a way to turn Tesla’s demise into a flurry of opportunity… In fact, he has not lost a single trade on Tesla this year. As of this mailing he’s 9 for 9 with incredible wins under his belt. Just see for yourself.May 17, 2024 | markets.businessinsider.comBuy Rating for Barinthus Biotherapeutics Backed by Strong Financials and Promising Clinical TrialsApril 30, 2024 | msn.comWhat is AstraZeneca Vaccine? Know the Recently Discovered Side Effects of the COVID-19 AntibodyApril 19, 2024 | markets.businessinsider.comBuy Rating on Barinthus Biotherapeutics Backed by Promising Clinical Trials and Strong Valuation ProspectsApril 6, 2024 | msn.comLondon is a bad place to raise money, says life sciences tsar Sir John BellMarch 2, 2024 | seekingalpha.comArbutus Biopharma Corporation (ABUS) Q4 2023 Earnings Call TranscriptJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.January 8, 2024 | markets.businessinsider.comPositive Clinical Outlook and Strong Capital Position Justify Buy Rating for Barinthus BiotherapeuticsJanuary 8, 2024 | finanznachrichten.deBarinthus Biotherapeutics: Barinthus Bio Provides a Financial Update and Announces Anticipated 2024 Corporate MilestonesJanuary 5, 2024 | finance.yahoo.comBarinthus Bio Provides a Financial Update and Announces Anticipated 2024 Corporate MilestonesDecember 22, 2023 | markets.businessinsider.comBuy Rating for Barinthus Biotherapeutics: Promising Pipeline and Strategic Partnerships Signal Investment OpportunityDecember 21, 2023 | markets.businessinsider.comBarinthus Biotherapeutics Collaborates With CEPI And University Of Oxford For New MERS VaccineDecember 21, 2023 | finance.yahoo.comNew partnership aims to advance vaccine against MERS coronavirusDecember 13, 2023 | finance.yahoo.comInfluenza Vaccine Market to grow by USD 2.93 billion from 2022 to 2027; North America to account for 54% of market growth - TechnavioNovember 28, 2023 | markets.businessinsider.comAnalysts’ Top Healthcare Picks: Barinthus Biotherapeutics (BRNS), Anavex Life Sciences (AVXL)November 15, 2023 | finance.yahoo.comBarinthus Biotherapeutics plc (BRNS)See More Headlines Receive VACC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vaccitech and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/12/2021Today7/26/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:VACC CUSIPN/A CIK1828185 Webwww.vaccitech.co.uk Phone44-18-6581-8808FaxN/AEmployees33Year FoundedN/APrice Target and Rating Average Stock Price Target$7.63 High Stock Price Target$12.00 Low Stock Price Target$3.25 Potential Upside/Downside+456.6%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.43) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$5.34 million Net Margins-409.18% Pretax Margin-442.00% Return on Equity-23.41% Return on Assets-20.85% Debt Debt-to-Equity RatioN/A Current Ratio15.26 Quick Ratio15.26 Sales & Book Value Annual Sales$13.42 million Price / Sales3.93 Cash Flow$0.07 per share Price / Cash Flow19.30 Book Value$6.52 per share Price / Book0.21Miscellaneous Outstanding Shares38,547,000Free Float36,234,000Market Cap$52.81 million OptionableNot Optionable Beta-0.40 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesMr. William J. Enright MBA (Age 60)CEO & Director Comp: $916.62kMs. Sarah GilbertCo-FounderMr. Adrian Hill Ph.D.Co-Founder & Scientific AdvisorMs. Gemma Brown (Age 33)CFO & Company Secretary Mr. Chris Ellis (Age 63)Chief Operating Officer Dr. Nadege Pelletier Ph.D. (Age 45)Chief Scientific Officer Mr. Graham Griffiths (Age 44)Chief Business Officer Ms. Elizabeth Eagling-Vose M.B.A.Head of Clinical OperationsBernie McDonaldHead of IPGeoffrey LynnSenior Vice President of Synthetic ImmunotherapiesMore ExecutivesKey CompetitorsShattuck LabsNASDAQ:STTKAbeona TherapeuticsNASDAQ:ABEOGeneration BioNASDAQ:GBIOTrevi TherapeuticsNASDAQ:TRVIGreenwich LifeSciencesNASDAQ:GLSIView All CompetitorsInstitutional OwnershipM&G PlcBought 5,197,349 shares on 5/10/2024Ownership: 13.483%View All Institutional Transactions VACC Stock Analysis - Frequently Asked Questions How have VACC shares performed this year? Vaccitech's stock was trading at $3.69 at the beginning of 2024. Since then, VACC shares have decreased by 62.9% and is now trading at $1.37. View the best growth stocks for 2024 here. How were Vaccitech's earnings last quarter? Vaccitech plc (NASDAQ:VACC) posted its earnings results on Friday, November, 12th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.38) by $0.25. The company earned $0.02 million during the quarter, compared to the consensus estimate of $1.65 million. Vaccitech had a negative net margin of 409.18% and a negative trailing twelve-month return on equity of 23.41%. When did Vaccitech IPO? Vaccitech (VACC) raised $110 million in an IPO on Friday, April 30th 2021. The company issued 6,500,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, Jefferies, Barclays and William Blair served as the underwriters for the IPO and H.C. Wainwright & Co., LLC was co-manager. How do I buy shares of Vaccitech? Shares of VACC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:VACC) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredWhy is NVDA stumbling?July is historically the best month of the year for U.S. stocks. So why are everyone’s favorite tech stocks...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vaccitech plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Vaccitech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
